CYBERNANO

Their core work

CYBERNANO is a French technology SME specializing in nanomedicine and advanced pharmaceutical manufacturing, with a focus on the production and quality control of nano-scale drug delivery systems. Their work spans two distinct but complementary domains: quality-by-design frameworks for high-risk medical devices, and the microfluidic manufacture of lipid nanoparticles and extracellular vesicles for RNA-based therapeutics. In the EXPERT project, they contribute to expanding manufacturing platforms for mRNA medicines targeting immuno-oncology and heart failure — placing them at the applied end of one of the fastest-moving areas in modern medicine. Their profile suggests a company that translates nanotechnology from laboratory scale into GMP-compliant manufacturing processes.

What they specialise in

How they've shifted over time

CYBERNANO's two projects both started in 2019, so there is no true chronological shift — but the thematic contrast between the two is sharp and telling. Their earlier-coded project (TBMED) was grounded in medical device validation infrastructure: testing beds, open innovation frameworks, and quality-by-design principles. Their second project (EXPERT) moves decisively into advanced nanomedicine: lipid nanoparticles, extracellular vesicles, microfluidic manufacture, and mRNA delivery for serious diseases. The direction of travel is from device quality assurance toward nano-pharmaceutical manufacturing — a significant deepening of technical specialization toward biologically active nano-carriers and RNA medicines.

CYBERNANO is moving toward GMP-grade manufacturing of RNA-based nanomedicines, making them a potential partner for any consortium working on mRNA therapeutics, lipid nanoparticle scale-up, or nano-drug delivery platforms.

How they like to work

CYBERNANO has participated in both projects as a consortium member, never as coordinator — a pattern consistent with a specialist SME that contributes defined technical capabilities rather than project management. With 30 unique partners across just 2 projects, they operate in large, multi-partner consortia (roughly 15 partners per project), suggesting they are comfortable navigating complex, multi-stakeholder European research environments. This scale of partner diversity for such a small project portfolio indicates they integrate readily into large consortia as a focused technical contributor.

CYBERNANO has built a notably broad network for an SME with only two projects: 30 unique partners across 12 countries. This cross-border exposure across European research networks suggests they are well-connected despite their small size, and would bring established consortium relationships to any future project.

What sets them apart

CYBERNANO occupies a specific niche at the intersection of nano-scale drug delivery manufacturing and pharmaceutical quality systems — a combination that is rare among SMEs. Their simultaneous engagement in medical device testing infrastructure (TBMED) and mRNA nanomedicine manufacturing (EXPERT) means they bridge regulatory quality frameworks with cutting-edge nano-fabrication techniques. For a consortium building a project on mRNA therapeutics, lipid nanoparticle scale-up, or nano-drug GMP compliance, CYBERNANO offers both technical manufacturing depth and familiarity with quality-by-design regulatory requirements.

Highlights from their portfolio

• EXPERT
  The largest and longest project (2019-2025, EUR 339,625), targeting mRNA therapeutics for immuno-oncology and heart failure via lipid nanoparticles and extracellular vesicles — positioning CYBERNANO within one of the highest-impact areas of modern medicine.
• TBMED
  Highest EC contribution (EUR 415,971) and focuses on open innovation testing infrastructure for high-risk medical devices, demonstrating CYBERNANO's regulatory and quality assurance competence beyond pure nanomedicine.